Skip to main content

Raise Your Profile

Whether you are looking to attract a new business client, investment and partnering deal flow or talent, among other goals, One Nucleus offers a wide range of opportunities to raise your profile to our members and to the Greater Cambridge cluster in particular.
Raise Your Profile
  • Discounts for Members

    Discounts for Members

    Members can take advantage of discounts on a wide range of products and services to maximise their return on the member subscription, often recovering multiples of the fees paid. Receive discounted rates on laboratory supplies, services, key industry events and more.
    Learn more
  • Connect with Our Network

    Connect with Our Network

    A key advantage to any company joining One Nucleus is the ability to connect to potential partners, investors, service providers, clients and their peers for knowledge-sharing. We do this through our varied range of informative networking events, which tend to be situated throughout Cambridge and London.
    Learn more
  • Build the Best Teams

    Build the Best Teams

    One Nucleus recognises that a company’s employees are its most valuable asset and the competition for talented and skilled employees has never been fiercer in the region’s life science sector. One Nucleus offers a range of services and engagement opportunities in this critical area to help support our members and maintain the reputation of the sector.
    Learn more

Events

Connecting and meeting with business partners, fellow innovators and key advisers is a vital part of everyone's endeavours since it enables knowledge exchange and onward contact for mutual and collective success. Complementing the wider One Nucleus support activities our portfolio of events is designed to meet the needs of our network in terms of content, format, timing, peer-to-peer engagements and modes of delivery.
  • Events
  • Events
  • Events
  • Events

Membership Overview

With Gold and Silver membership options, our 400 company members and their staff can benefit from a wide variety of savings, profiling opportunities, and more.
  • Membership

About One Nucleus

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. 
  • About

Senior GMP Production Scientist

We are currently looking for a Senior GMP Production Scientist to join a leading biopharmaceutical CDMO based in the South West of the UK to join their team.

Our client specialises in GMP manufacturing of advanced therapy and biologic products. As a Senior GMP Production Scientist, you will take the lead in supervising GMP manufacturing operations for a range of clinical products. This includes overseeing production teams, supporting technology transfer, and ensuring compliance across ATMP and biologics projects.

Principal Scientist PKPD

We are recruiting a Principal Scientist, Non-Clinical PKPD, to join a leading Pharmaceutical company based in the Berkshire area for 12 months. As the Principal Scientist, Non-Clinical PKPD, you will be responsible for driving the quantitative integrated strategy of pharmacokinetics and pharmacology to bring differentiated solutions to patients.

KEY DUTIES AND RESPONSIBILITIES:

Your duties as the Principal Scientist, Non-Clinical PKPD will be varied however the key duties and responsibilities are as follows:

10 Common Lab Procurement Mistakes and How to Fix Them

R&D procurement might seem straightforward, but behind the scenes, small mistakes can cause big headaches for labs. Mismanaged orders, unexpected product delays, and budget overruns can derail even the best-laid research plans.

The good news? With a little insight and a few process tweaks, many common pitfalls are easy to avoid. Let’s take a look at the top lab procurement mistakes and how you can sidestep them to keep your research moving forward without disruption.

Life Sciences Under Cyber Siege: Protecting Data, IP & Supply Chains from Growing Threats

Cybercriminals are increasingly targeting life sciences firms - drawn by valuable IP, sensitive data, and complex, digitally connected supply chains. A successful attack can halt operations, leak critical assets, and damage hard-earned trust.

This webinar explores the unique cyber risks facing the life sciences sector and what can be done to reduce exposure, improve resilience, and how to respond effectively when the worst happens.

Why Attend?

Understand why life sciences is a top target - and how attackers are exploiting sector-specific vulnerabilities.

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. 

iPSC protocol opens the door to explore male infertility treatments

Amsbio reports how the Sasaki Lab within the School of Veterinary Medicine at the University of Pennsylvania (USA) devised a protocol in which induced pluripotent stem cells (iPSCs) could be utilized to produce reconstituted human testes.

Since the original 2020 publication of their groundbreaking research, Dr Kotaro Sasaki’s team has made significant progress in reconstituting human testis-like tissue from iPSCs.

First non-hormonal menopause treatment approved for use in the UK by the MHRA, with early-stage development at Stevenage Bioscience Catalyst

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved elinzanetant (branded as Lynkuet™) for the treatment of moderate to severe hot flushes and night sweats associated with menopause. These symptoms, also known as vasomotor symptoms, affect a significant proportion of women and can have a considerable impact on quality of life.

Subscribe to